Clinical trial · Observational
The STAR Prospective Clinical Series
The DFINE STAR™ Tumor Ablation Prospective Clinical Series
NCT02217150CI-TRIAL-00025570PCScompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prospective clinical series to gather post tumor ablation clinical outcomes from subjects with painful spinal metastases following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tumor Ablation System.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastasis to Vertebral Column | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (1)
- label
- Metastatic Lesions to the spine
- description
- Patients over the age of 18 receiving treatment using the DFINE Inc. STAR tumor ablation system for palliation of painful metastases of the spine.
Primary outcomes (1)
- measure
- Change in Pain
- timeFrame
- 1 month
- description
- Mean change from baseline in worst pain score per NRPS at one month
Secondary outcomes (3)
- measure
- Change in Quality of Life
- timeFrame
- 3 months
- description
- Change from baseline at each visit using Functional Assessment of Cancer Therapy - Bone Pain (FACT-BP)
- measure
- Change if Quality of Life
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 100 Years
Show eligibility criteria text
Inclusion Criteria: * The STAR™ Tumor Ablation System is indicated for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body. Exclusion Criteria: * The device is contraindicated in subjects with heart pacemakers, or other electronic device implants. * The device is contraindicated in vertebral body levels C1-7.
References
Publications (0)
Data not yet available
No reference posted for this study.